Myelodysplastic Syndrome - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Myelodysplastic Syndromes > What Your Doctor is Reading About Myelodysplastic Syndromes > Review Articles

Review Articles

1. Drug resistance and methylation in myelodysplastic syndrome.

Author: Vidal DO; Lopes LF; Valera ET;
Institution: Laboratory of Molecular Biology and Genomics, Ludwig Institute for Cancer Research--Sao Paulo Branch, Brazil. dvidal@ludwig.org.br
Journal: Curr Pharm Biotechnol. 2007 Apr;8(2):77-81.
Abstract URL: Click here to view abstract

2. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.

Author: Steensma DP;
Institution
Journal: Haematologica. 2007 Jun;92(6):723-7.

3. Comparison of megadose methylprednisolone versus conventional dose prednisolone in hematologic disorders.

Author: Yetgin S; Ozsoylu S;
Institution: Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. yetgins@hacettepe.edu.tr
Journal: J Pediatr Hematol Oncol. 2007 Apr;29(4):253-9.
Abstract URL: Click here to view abstract

4. Risk-based management of myelodysplastic syndrome.

Author: Steensma DP; Tefferi A;
Institution: Mayo Clinic, Rochester, Minnesota, USA. steensma.david@mayo.edu
Journal: Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62.
Abstract URL: Click here to view abstract

5. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.

Author: Stevenson JG; Natale JJ;
Institution: Department of Pharmacy Services, University of Michigan Hospitals and Health Centers, and the College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-0008, USA. jimsteve@med.umich.edu
Journal: Pharmacotherapy. 2007 Mar;27(3):434-46.
Abstract URL: Click here to view abstract

6. Deferasirox.

Author: Stumpf JL;
Institution: University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan, USA.
Journal: Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16.
Abstract URL: Click here to view abstract

7. Recent advances in myelodysplastic syndromes.

Author: Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H;
Institution: Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh, PA 15224, USA. rshadduck@msn.com
Journal: Exp Hematol. 2007 Apr;35(4 Suppl 1):137-43.
Abstract URL: Click here to view abstract

8. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.

Author: Jabbour E; Kantarjian HM; Koller C; Taher A;
Institution: Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Cancer. 2008 Mar 1;112(5):1089-95.
Abstract URL: Click here to view abstract

9. Treatment strategies in myelodysplastic syndromes.

Author: Atallah E; Garcia-Manero G;
Institution: Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Journal: Cancer Invest. 2008 Mar;26(2):208-16.
Abstract URL: Click here to view abstract

10. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.

Author: Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA;
Institution: St. Johannes Hospital, Medizinische Klinik II, An der Abtei 7-11, 47166 Duisburg, Germany. gia@krebs-duisburg.de
Journal: Ann Hematol. 2008 May;87(5):345-52. Epub 2008 Feb 12.
Abstract URL: Click here to view abstract

11. Iron overload in myelodysplastic syndromes.

Author: Mahesh S; Ginzburg Y; Verma A;
Institution: Albert Einstein College of Medicine, Cancer Center, Bronx, NY, USA.
Journal: Leuk Lymphoma. 2008 Mar;49(3):427-38.
Abstract URL: Click here to view abstract

12. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.

Author: Niemeyer CM; Kratz CP;
Institution: Department of Paediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany. charlotte.niemeyer@uniklinik-freiburg.de
Journal: Br J Haematol. 2008 Mar;140(6):610-24.
Abstract URL: Click here to view abstract

13. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?

Author: Marcondes M; Deeg HJ;
Institution: Fred Hutchinson Cancer Research Center and the University of Washington, 1100 Fairview Avenue North, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA.
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):67-77.
Abstract URL: Click here to view abstract

14. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.

Author: Hellstrom-Lindberg E; Malcovati L;
Institution: Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. Eva.Hellstrom-Lindberg@ki.se
Journal: Blood Rev. 2008 Mar;22(2):75-91. Epub 2008 Feb 20.
Abstract URL: Click here to view abstract

15. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series.

Author: Elghetany MT;
Institution: Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0743, USA. melgheta@utmb.edu
Journal: Arch Pathol Lab Med. 2007 Jul;131(7):1110-6.
Abstract URL: Click here to view abstract

16. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.

Author: Wood BL;
Institution: Hematopathology Laboratory, Box # 357110, Department of Laboratory Medicine, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA. woodbl@u.washington.edu
Journal: Clin Lab Med. 2007 Sep;27(3):551-75, vii.
Abstract URL: Click here to view abstract

17. Use of hypomethylating agents in myelodysplastic syndromes.

Author: Atallah E; Garcia-Manero G;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52.
Abstract URL: Click here to view abstract

18. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.

Author: Ortega J; List A;
Institution: Department of Interdisciplinary Oncology, University of South Florida, College of Medicine and the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA.
Journal: Curr Opin Oncol. 2007 Nov;19(6):656-9.
Abstract URL: Click here to view abstract

19. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.

Author: Valcarcel D; Martino R; Valcarcel D; Martino R;
Institution: Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. dvalcarcel@santpau.es
Journal: Curr Opin Oncol. 2007 Nov;19(6):660-6.
Abstract URL: Click here to view abstract

20. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Author: Kerbauy DB; Deeg HJ;
Institution: Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98109-1024, USA.
Journal: Exp Hematol. 2007 Nov;35(11):1739-46.
Abstract URL: Click here to view abstract

21. Myelodysplastic syndromes.

Author: Nimer SD;
Institution: Division of Hematologic Oncology and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Journal: Blood. 2008 May 15;111(10):4841-51.
Abstract URL: Click here to view abstract

22. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.

Author: Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA;
Institution: Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ont., Canada.
Journal: Leuk Res. 2006 Feb;30(2):233-9. Epub 2005 Jul 25.
Abstract URL: Click here to view abstract

23. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.

Author: Balducci L;
Institution: Department of Interdisciplinary Oncology, Geriatric Section, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA. balducci@moffitt.usf.edu
Journal: Cancer. 2006 May 15;106(10):2087-94.
Abstract URL: Click here to view abstract

24. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.

Author: de Lima M; Giralt S;
Institution: Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, TX 77033, USA. mdelima@mdanderson.org
Journal: Semin Hematol. 2006 Apr;43(2):107-17.
Abstract URL: Click here to view abstract

25. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

Author: Nimer SD; Nimer SD;
Institution: Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA. s-nimer@mskcc.org
Journal: J Clin Oncol. 2006 Jun 1;24(16):2576-82.
Abstract URL: Click here to view abstract

26. Myelodysplasia: when to treat and how.

Author: Larson RA;
Institution: Department of Medicine and Cancer Research Center, University of Chicago Pritzker School of Medicine, MC-2115, 5841 S. Maryland Avenue, Chicago, IL 60637, USA. rlarson@medicine.bsd.uchicago.edu
Journal: Best Pract Res Clin Haematol. 2006;19(2):293-300.
Abstract URL: Click here to view abstract

27. The myelodysplastic syndromes: diagnosis and treatment.

Author: Steensma DP; Bennett JM; Steensma DP; Bennett JM;
Institution: Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. steensma.david@mayo.edu
Journal: Mayo Clin Proc. 2006 Jan;81(1):104-30.
Abstract URL: Click here to view abstract

28. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.

Author: Kuykendall JR;
Institution: Department of Biomedical and Pharmaceutical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810-1599, USA. j-kuykendall@onu.edu
Journal: Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6.
Abstract URL: Click here to view abstract

29. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.

Author: Lindberg EH;
Institution: Karolinska Institutet, Dept of Medicine, Div of Hematology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. eva.hellstrom-lindberg@medhs.ki.se
Journal: Curr Drug Targets. 2005 Sep;6(6):713-25.
Abstract URL: Click here to view abstract

30. New agents in the treatment of childhood leukemias and myelodysplastic syndromes.

Author: Corey SJ;
Institution: Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Box 853, 1515 Holcombe Boulevard, Houston, TX 77030, USA. sjcorey@mdanderson.org
Journal: Curr Oncol Rep. 2005 Nov;7(6):399-405.
Abstract URL: Click here to view abstract

31. Developmental therapeutics for myelodysplastic syndromes.

Author: Naing A; Sokol L; List AF; Naing A; Sokol L; List AF;
Institution: H. Lee Moffitt Cancer Center & Research Institute, University of South Florida College of Medicine, Tampa, FL, USA.
Journal: J Natl Compr Canc Netw. 2006 Jan;4(1):78-82.
Abstract URL: Click here to view abstract

32. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.

Author: Greenberg PL;
Institution: Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305-5821, USA. peterg@stanford.edu
Journal: J Natl Compr Canc Netw. 2006 Jan;4(1):91-6.
Abstract URL: Click here to view abstract

33. Immunomodulatory drugs in myelodysplastic syndromes.

Author: Galili N; Raza A; Galili N; Raza A;
Institution: The Radhey Khanna MDS Center, University of Massachusetts Medical Centre, Division of Hematology, Department of Medicine, 364 Plantation Street, LRB 208, Worcester, MA 01605, USA. naomi.galili@umassmed.edu
Journal: Expert Opin Investig Drugs. 2006 Jul;15(7):805-13.
Abstract URL: Click here to view abstract

34. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

Author: List AF; Baker AF; Green S; Bellamy W;
Institution: Malignant Hematology Program, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. listaf@moffitt.org
Journal: Cancer Control. 2006 Dec;13 Suppl:4-11.
Abstract URL: Click here to view abstract

35. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.

Author: List AF;
Institution: Malignant Hematology Program, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. listaf@moffitt.org
Journal: Cancer Control. 2006 Dec;13 Suppl:12-6.
Abstract URL: Click here to view abstract

36. Myelodysplastic syndromes: the complexity of stem-cell diseases.

Author: Corey SJ; Minden MD; Barber DL; Kantarjian H; Wang JC; Schimmer AD;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. sjcorey@mdanderson.org
Journal: Nat Rev Cancer. 2007 Feb;7(2):118-29.
Abstract URL: Click here to view abstract

37. Evolving classifications of the myelodysplastic syndromes.

Author: Komrokji RS; Bennett JM;
Institution: Department of Medicine, University of Cincinnati and Veterans, Administration Medical Center, Cincinnati, Ohio, USA.
Journal: Curr Opin Hematol. 2007 Mar;14(2):98-105.
Abstract URL: Click here to view abstract

38. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.

Author: Melchert M; Kale V; List A;
Institution: Malignant Hematology Division, Department of Medicine, University of South Florida College of Medicine and the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA. melcheme@moffitt.usf.edu
Journal: Curr Opin Hematol. 2007 Mar;14(2):123-9.
Abstract URL: Click here to view abstract

39. Umbilical cord blood transplantation for myeloid malignancies.

Author: Brunstein CG; Baker KS; Wagner JE; Brunstein CG; Baker KS; Wagner JE;
Institution: Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. bruns072@umn.edu
Journal: Curr Opin Hematol. 2007 Mar;14(2):162-9.
Abstract URL: Click here to view abstract

40. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Author: Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstocker M; Ruter B; Sperr WR; Stauder R; Wells DA; Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstocker M; Ruter B; Sperr WR; Stauder R; Wells DA;
Institution: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. peter.valent@meduniwien.ac.at
Journal: Leuk Res. 2007 Jun;31(6):727-36. Epub 2007 Jan 25.
Abstract URL: Click here to view abstract

41. Clinical relevance of cytogenetics in myelodysplastic syndromes.

Author: Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M;
Institution: Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Fondazione Policlinico San Matteo IRCCS, Pavia, Italy. p.bernasconi@smatteo.pv.it
Journal: Ann N Y Acad Sci. 2006 Nov;1089:395-410.
Abstract URL: Click here to view abstract

42. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.

Author: Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G;
Institution: Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano-Torino, Italy. daniela.cilloni@unito.it
Journal: Ann N Y Acad Sci. 2006 Nov;1089:411-23.
Abstract URL: Click here to view abstract

43. Immunomodulation in myelodysplastic syndromes.

Author: Sekeres MA; List A;
Institution: Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. sekerem@ccf.org
Journal: Best Pract Res Clin Haematol. 2006;19(4):757-67.
Abstract URL: Click here to view abstract

44. Advances in erythropoietic growth factor therapy for myelodysplastic syndromes.

Author: Mundle SD;
Institution: Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA. smundle@obius.jnj.com
Journal: Expert Opin Biol Ther. 2006 Nov;6(11):1099-104.
Abstract URL: Click here to view abstract

45. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.

Author: Deschler B; de Witte T; Mertelsmann R; Lubbert M; Deschler B; de Witte T; Mertelsmann R; Lubbert M;
Institution: Department of Hematology Oncology, University of Freiburg Hugstetterstr. 55, D-79106 Freiburg, Germany.
Journal: Haematologica. 2006 Nov;91(11):1513-22.
Abstract URL: Click here to view abstract

46. The role of decitabine in the treatment of myelodysplastic syndromes.

Author: Atallah E; Kantarjian H; Garcia-Manero G;
Institution: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Expert Opin Pharmacother. 2007 Jan;8(1):65-73.
Abstract URL: Click here to view abstract

47. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.

Author: Faderl, Stefan; Kantarjian, Hagop M;
Institution: Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. sfaderl@mdanderson.org
Journal: Nat Clin Pract Oncol 2005 Jul;2(7):348-55.
Abstract URL: Click here to view abstract

48. Azacitidine.

Author: Issa, Jean-Pierre; Kantarjian, Hagop;
Institution: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA. jpissa@mdanderson.org
Journal: Nat Rev Drug Discov 2005 May;Suppl:S6-7.
Abstract URL: Click here to view abstract

49. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).

Author: Ogasawara, Toshie; Yasuyama, Masako; Kawauchi, Kiyotaka;
Institution: Tokyo Women's Medical University Daini Hospital, Department of Medicine, Tokyo 116-8567, Japan.
Journal: Am J Hematol 2005 Jun;79(2):136-41.
Abstract URL: Click here to view abstract

50. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions.

Author: Giralt, Sergio;
Institution: University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 462, Houston, TX 77030, USA.
Journal: Curr Hematol Rep 2005 May;4(3):200-7.
Abstract URL: Click here to view abstract

51. New agents in myelodysplastic syndromes.

Author: Jabbour, Elias J; Giles, Francis J;
Institution: Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77063, USA.
Journal: Curr Hematol Rep 2005 May;4(3):191-9.
Abstract URL: Click here to view abstract

52. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.

Author: Komrokji, Rami S; Bennett, John M;
Institution: James P Wilmot Cancer Center, Strong Memorial Hospital, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Journal: Curr Hematol Rep 2005 May;4(3):175-81.
Abstract URL: Click here to view abstract